Logo image of HEPA

HEPION PHARMACEUTICALS INC (HEPA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:HEPA - US4268974015 - Common Stock

0.318 USD
-0.07 (-18.79%)
Last: 5/12/2025, 8:00:01 PM
0.1748 USD
-0.14 (-45.03%)
After Hours: 5/12/2025, 8:00:01 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to HEPA. HEPA was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of HEPA have multiple concerns. HEPA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

HEPA had negative earnings in the past year.
HEPA had a negative operating cash flow in the past year.
HEPA had negative earnings in each of the past 5 years.
In the past 5 years HEPA always reported negative operating cash flow.
HEPA Yearly Net Income VS EBIT VS OCF VS FCFHEPA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

HEPA has a Return On Assets of -817.53%. This is amonst the worse of the industry: HEPA underperforms 96.97% of its industry peers.
Industry RankSector Rank
ROA -817.53%
ROE N/A
ROIC N/A
ROA(3y)-387.74%
ROA(5y)-247.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HEPA Yearly ROA, ROE, ROICHEPA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

HEPA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HEPA Yearly Profit, Operating, Gross MarginsHEPA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for HEPA has been reduced compared to 1 year ago.
Compared to 5 years ago, HEPA has less shares outstanding
HEPA has a worse debt/assets ratio than last year.
HEPA Yearly Shares OutstandingHEPA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
HEPA Yearly Total Debt VS Total AssetsHEPA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

HEPA has an Altman-Z score of -246.42. This is a bad value and indicates that HEPA is not financially healthy and even has some risk of bankruptcy.
HEPA has a worse Altman-Z score (-246.42) than 96.46% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -246.42
ROIC/WACCN/A
WACCN/A
HEPA Yearly LT Debt VS Equity VS FCFHEPA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 0.51 indicates that HEPA may have some problems paying its short term obligations.
The Current ratio of HEPA (0.51) is worse than 91.92% of its industry peers.
HEPA has a Quick Ratio of 0.51. This is a bad value and indicates that HEPA is not financially healthy enough and could expect problems in meeting its short term obligations.
HEPA's Quick ratio of 0.51 is on the low side compared to the rest of the industry. HEPA is outperformed by 90.40% of its industry peers.
Industry RankSector Rank
Current Ratio 0.51
Quick Ratio 0.51
HEPA Yearly Current Assets VS Current LiabilitesHEPA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for HEPA have decreased by -4.41% in the last year.
EPS 1Y (TTM)-4.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

HEPA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.78% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y98.11%
EPS Next 2Y41.12%
EPS Next 3Y25.77%
EPS Next 5Y14.78%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HEPA Yearly Revenue VS EstimatesHEPA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 200M 400M 600M 800M
HEPA Yearly EPS VS EstimatesHEPA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -20K -40K -60K -80K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HEPA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HEPA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HEPA Price Earnings VS Forward Price EarningsHEPA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HEPA Per share dataHEPA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -200 -400 -600

4.3 Compensation for Growth

A more expensive valuation may be justified as HEPA's earnings are expected to grow with 25.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.12%
EPS Next 3Y25.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HEPA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HEPION PHARMACEUTICALS INC

NASDAQ:HEPA (5/12/2025, 8:00:01 PM)

After market: 0.1748 -0.14 (-45.03%)

0.318

-0.07 (-18.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-19 2025-05-19/amc
Earnings (Next)08-11 2025-08-11
Inst Owners7.21%
Inst Owner Change-100%
Ins Owners0.02%
Ins Owner Change0%
Market Cap3.49M
Revenue(TTM)N/A
Net Income(TTM)-13.19M
Analysts82.86
Price TargetN/A
Short Float %0.02%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-616
EYN/A
EPS(NY)-5.3
Fwd EYN/A
FCF(TTM)-1.66
FCFYN/A
OCF(TTM)-1.66
OCFYN/A
SpS0
BVpS-0.17
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -817.53%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-387.74%
ROA(5y)-247.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.51
Quick Ratio 0.51
Altman-Z -246.42
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y98.11%
EPS Next 2Y41.12%
EPS Next 3Y25.77%
EPS Next 5Y14.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y57.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.45%
OCF growth 3YN/A
OCF growth 5YN/A

HEPION PHARMACEUTICALS INC / HEPA FAQ

What is the fundamental rating for HEPA stock?

ChartMill assigns a fundamental rating of 1 / 10 to HEPA.


Can you provide the valuation status for HEPION PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 1 / 10 to HEPION PHARMACEUTICALS INC (HEPA). This can be considered as Overvalued.


What is the profitability of HEPA stock?

HEPION PHARMACEUTICALS INC (HEPA) has a profitability rating of 0 / 10.


How financially healthy is HEPION PHARMACEUTICALS INC?

The financial health rating of HEPION PHARMACEUTICALS INC (HEPA) is 1 / 10.